Dana-Farber/New Hampshire Oncology-Hematology — Londonderry, New Hampshire

Dana-Farber/New Hampshire Oncology-Hematology is a clinical research site located in Londonderry, New Hampshire, United States 03053.

Crixeo Clinical Trials Trust Score: 20/100 (FAILING). This profile has not yet been claimed by the site owner.

Dana-Farber/New Hampshire Oncology-Hematology has participated in 14 clinical trials with 7 currently active.

Therapeutic areas: Breast Cancer, Cancer, Venous Thromboembolism.

Sponsors: Dana-Farber Cancer Institute, Alliance Foundation Trials, LLC., American Society of Clinical Oncology.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Londonderry

Browse all research sites in New Hampshire · View every site in Londonderry

Sponsor Feasibility Report

Trust Score: 20/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber/New Hampshire Oncology-Hematology?

Dana-Farber/New Hampshire Oncology-Hematology has a Crixeo Trust Score of 20/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber/New Hampshire Oncology-Hematology conducted?

Dana-Farber/New Hampshire Oncology-Hematology has 14 clinical trials on record, with 7 currently active. Their work covers Breast Cancer, Cancer, Venous Thromboembolism.

Is Dana-Farber/New Hampshire Oncology-Hematology accredited by Crixeo Clinical Trials?

Dana-Farber/New Hampshire Oncology-Hematology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana-Farber/New Hampshire Oncology-Hematology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.